Howard Amital

Howard Amital

Auto-generated profile, based on publicly available information

Howard Amital

Department of Medicine D, Meir Medical Center, Tshernichovsky 59, Kfar-Saba, 44281, Israel

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2009 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
YAYoav Arnson
Yoav Arnson
HAHoward Amital
Howard Amital
SGSerena Guiducci
Serena Guiducci
MMMarco Matucci‐Cerinic
Marco Matucci‐Cerinic
GVGabriele Valentini
Gabriele Valentini
YSYehuda Shoenfeld
Yehuda Shoenfeld

1 November 2006 in Journal of Psychosomatic Research
Verified
Journal Article
Closed access
DADaniella Amital
Daniella Amital
Leah FostickLeah Fostick
Leah Fostick
MPMichael L. Polliack
Michael L. Polliack
SSShlomo Segev
Shlomo Segev
JZJoseph Zohar
Joseph Zohar
HAHoward Amital
Howard Amital

3 July 2009 in Rheumatology
Verified
Journal Article
Open access
PDF file
HAHoward Amital
Howard Amital
YAYoav Arnson
Yoav Arnson
GCGabriel Chodick
Gabriel Chodick
VSVarda Shalev
Varda Shalev
Objective. MTX hepatotoxicity is considered to occur more frequently in patients with psoriasis than in patients with RA. However, toxicity guidelines are based on reports from studies with small sample sizes and limited follow-up periods. The current study's objective was to examine the long-term risk of MTX hepatotoxicity based on a database review of patients with RA or psoriasis, and to examine whether the two populations differed. Methods. We conducted a retrospective cohort review among members of a large health maintenance organization (HMO) in Israel who were diagnosed with either RA (n = 119) or psoriasis (n = 690) and who had purchased at least one dose of MTX. Liver function analyses were performed serially in these patients during the follow-up. All abnormal assays were recorded in the computerized database of the HMO. Results. Both groups had hepatic enzyme elevation; the pre-disposing factors predictive of liver damage were female gender and a higher cumulative dose of MTX (hazard ratios, 1.46 and 1.07, respectively, P < 0.001). Age, concurrent diseases and type of disease had no influence on susceptibility to liver damage. No statistically significant difference was detected in any abnormal liver function test among patients with either RA or psoriasis. Conclusion. Our study did not corroborate previous findings of significant differences between psoriasis patients and RA patients concerning susceptibility to hepatotoxicity from MTX therapy. The only significant factor predicting a higher risk of hepatic damage was female gender.

1 January 2008
Verified
Journal Article
Closed access
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
GZGisele Zandman-Goddard
Gisele Zandman-Goddard
LSLjudmila Stojanovich
Ljudmila Stojanovich
MCMaurizio Cutolo
Maurizio Cutolo
HAHoward Amital
Howard Amital
YSYaniv Sherer
Yaniv Sherer

1 September 2009 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LPLeeor Plot
Leeor Plot
HAHoward Amital
Howard Amital
OBOri Barzilai
Ori Barzilai
MRMaya Ram
Maya Ram
BNBizzaro Nicola
Bizzaro Nicola
YSYehuda Shoenfeld
Yehuda Shoenfeld

1 January 2008
Verified
Journal Article
Closed access
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
MBMiri Blank
Miri Blank
AAAbu-Shakra Abu-Shakra
Abu-Shakra Abu-Shakra
HAHoward Amital
Howard Amital
OBOri Barzilai
Ori Barzilai
MGM Eric Gershwin
M Eric Gershwin